Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2018 Financial Results February 25, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 28, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the fourth quarter and full-year 2018 after the close of market on Monday, February 25, 2019 . Company management will host a conference call
Toggle Summary Veracyte to Present at the 21st Annual Needham Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 9, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 21 st Annual Needham Growth Conference in New York City on  Tuesday, January 15, 2019  at  8:40


Date Event Details
Summary Toggle Feb 25, 2019 2:00 PM PST
Veracyte Fourth Quarter and Full Year 2018 Financial Results Webcast
Summary Toggle Jan 15, 2019 8:40 AM EST
21st Annual Needham Growth Conference


Title Documents

Corporate Presentation January 2019